Buchumschlag

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The inci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Penack, Olaf (VerfasserIn) , Peczynski, Christophe (VerfasserIn) , Koenecke, Christian (VerfasserIn) , Polge, Emmanuelle (VerfasserIn) , Sanderson, Robin (VerfasserIn) , Yakoub-Agha, Ibrahim (VerfasserIn) , Fegueux, Nathalie (VerfasserIn) , Daskalakis, Michael (VerfasserIn) , Collin, Matthew (VerfasserIn) , Dreger, Peter (VerfasserIn) , Kröger, Nicolaus (VerfasserIn) , Schanz, Urs (VerfasserIn) , Bloor, Adrian (VerfasserIn) , Ganser, Arnold (VerfasserIn) , Besley, Caroline (VerfasserIn) , Wulf, Gerald G. (VerfasserIn) , Novak, Urban (VerfasserIn) , Moiseev, Ivan (VerfasserIn) , Schoemans, Hélène (VerfasserIn) , Basak, Grzegorz W. (VerfasserIn) , Chabannon, Christian (VerfasserIn) , Sureda, Anna (VerfasserIn) , Glass, Bertram (VerfasserIn) , Peric, Zinaida (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 27 September 2023
In: Frontiers in immunology
Year: 2023, Jahrgang: 14, Pages: 1-10
ISSN:1664-3224
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1252811
Volltext
Verfasserangaben:Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Robin Sanderson, Ibrahim Yakoub-Agha, Nathalie Fegueux, Michael Daskalakis, Matthew Collin, Peter Dreger, Nicolaus Kröger, Urs Schanz, Adrian Bloor, Arnold Ganser, Caroline Besley, Gerald G. Wulf, Urban Novak, Ivan Moiseev, Hélène Schoemans, Grzegorz W. Basak, Christian Chabannon, Anna Sureda, Bertram Glass and Zinaida Peric
Beschreibung
Zusammenfassung:We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
Beschreibung:Gesehen am 22.01.2024
Beschreibung:Online Resource
ISSN:1664-3224

Ähnliche Einträge